close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

79.19 -0.44 (-0.55%)
Delayed Quote Updated: 12:43 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases ↗
Mirum Pharmaceuticals (NASDAQ:MIRM) said its Phase III EXPAND study of LIVMARLI, or maralixibat, met its primary endpoint and all prespecified secondary endpoints in pediatric patients with cholestatic... 
Via MarketBeat
News headline image
Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study ↗
Mirum Pharmaceuticals (NASDAQ:MIRM) reported positive top-line results from the Phase III portion of its AZURE-1 study evaluating brelovitug for chronic hepatitis delta, saying the investigational... 
Via MarketBeat
News headline image
Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript ↗
LIVMARLI sales surged 46% while management raised full-year guidance to $680M–$700M. 
Via The Motley Fool
Topics Earnings
Mirum Pharmaceuticals (NASDAQ:MIRM) Slides on Wider Loss and Volixibat Delay Despite Revenue Beat ↗
Via Chartmill
Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Dips After Q1 Revenue Beat and Guidance Raise, Despite Massive IPR&D Charge ↗
Via Chartmill
Mirum Pharmaceuticals (NASDAQ:MIRM) Reports Q4 2025 Revenue Beat and 2026 Outlook ↗
Via Chartmill
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Embodies the Minervini Growth Momentum Strategy ↗
Via Chartmill
News headline image
Mirum Pharmaceuticals Q2 Earnings Call Highlights ↗
Mirum Pharmaceuticals (NASDAQ:MIRM) reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million, while outlining... 
Via MarketBeat
Topics Earnings
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance ↗
Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and... 
Via MarketBeat
News headline image
Mirum Pharma: A Rare Disease Growth Story to Watch ↗
Mirum stock pulled back after earnings despite strong growth. Here’s why investors still see upside in the rare disease biotech company 
Via MarketBeat
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Offers a High-Growth Momentum and Technical Breakout Setup ↗
Via Chartmill
News headline image
Penn Capital Unloads 1.13 Million RealReal Shares Following Massive Stock Run-Up ↗
This online marketplace connects U.S. consumers with consigned luxury goods, spanning apparel, jewelry, art, and home products. 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Mirum (MIRM) Q1 2026 Earnings Call Transcript ↗
Mirum (MIRM) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term ↗
Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases. 
Via The Motley Fool
News headline image
Prediction: Buying This Biotech Stock Today Could Set You Up for Life ↗
This small biotech could grow much larger with some good news from its pipeline. 
Via The Motley Fool
News headline image
Mirum (MIRM) Q2 2025 Earnings Call Transcript ↗
Mirum (MIRM) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Mirum Pharma (MIRM) Earnings Call Transcript ↗
Mirum Pharma (MIRM) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Mirum (MIRM) Q1 2025 Earnings Call Transcript ↗
Mirum (MIRM) Q1 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗
This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms. 
Via The Motley Fool
News headline image
Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗
HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S. 
Via The Motley Fool
News headline image
Small-Cap Shudder: Russell 2000’s 1.9% Slide Signals Cracks in Economic Resilience
NEW YORK — The euphoric "small-cap comeback" that defined the opening weeks of 2026 came to a grinding halt on Thursday. The Russell 2000 index, the primary barometer for American small-cap health,... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Mirum (MIRM) Q4 2025 Earnings Call Transcript ↗
Mirum (MIRM) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
ACM Research’s AI Surge Collides With Export Controls and Chip Spending Cycles ↗
Penn Capital initiated a position in ACM Research, which supplies cleaning and plating tools used in advanced semiconductor manufacturing. As AI-driven chip designs grow more complex, precision... 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗
Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗
Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗
This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is Mirum Pharmaceuticals on a Strong Path to Profitability? ↗
The drugmaker is doing nearly everything else right. 
Via The Motley Fool
News headline image
Is Mirum Pharmaceuticals About to Soar in 2026? ↗
The future looks bright for this high-flying biotech stock. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.